Purpose To report the use of intranasal dexmedetomidine, an a 2 -adrenergic agonist for the acute treatment of refractory adrenergic crisis in patients with familial dysautonomia. Methods Case series. Results Three patients with genetically confirmed familial dysautonomia (case 1: 20-year-old male; case 2: 43-yearold male; case 3: 26-year-old female) received intranasal dexmedetomidine 2 mcg/kg, half of the dose in each nostril, for the acute treatment of adrenergic crisis. Within 8-17 min of administering the intranasal dose, the adrenergic crisis symptoms abated, and blood pressure and heart rate returned to pre-crises values. Adrenergic crises eventually resumed, and all three patients required hospitalization for investigation of the cause of the crises. Conclusions Intranasal dexmedetomidine is a feasible and safe acute treatment for adrenergic crisis in patients with familial dysautonomia. Further controlled studies are required to confirm the safety and efficacy in this population.
Introduction
Familial dysautonomia (FD, hereditary sensory and autonomic neuropathy type III, Riley-Day syndrome) is a genetic disorder caused by a founder mutation in the IKBKAP gene [6] . The disease has a complex neurological phenotype with marked blood pressure instability and disabling episodes of severe hypertension, tachycardia, nausea, retching and vomiting. These episodes, referred to as dysautonomic or adrenergic crises, are frequently accompanied by drooling, skin blotching, and behavioral changes, and they can be triggered by medical illness as well as by physical or emotional stress [5] . Episodes can occur multiple times a day and are the cause of frequent hospital admissions.
Centrally acting a 2 -agonists, such as clonidine, as well as benzodiazepines were classically used to restrain sympathetic activity during adrenergic crisis in patients with FD [7] . When adrenergic crises are emotionally-induced, treatment with these drugs may suffice. This, however, is not always the case, and patients often require escalating dosages of these drugs at home. Both clonidine and benzodiazepines have serious side effects, including excessive sedation, prolonged hypotension and respiratory depression. When a medical cause is the trigger of the crisis, it is the treatment of the underlying problem that will ultimately end the crisis. Still, symptomatic treatment is essential, and there is a need for short-acting effective agents. Carbidopa has been recently shown to be effective to reduce the frequency and severity of nausea in FD patients [4] , but its potential use as abortive short-acting treatment for adrenergic crisis has not been tested.
We have recently reported the successful use of intravenous dexmedetomidine, a centrally acting a 2 adrenergic agonist, to abort severe adrenergic crisis in patients with FD [2] . Dexmedetomidine has the advantage of having a rapid onset and very short half-life, but it requires intravenous administration in the hospital setting. Intranasal dexmedetomidine works almost as quickly as intravenous dexmedetomidine, has the same short half-life and can be easily and rapidly administered by non-medical personnel in the outpatient setting [3] .
Here we report our experience with three patients with FD in whom intranasal dexmedetomidine was used to temporarily abort adrenergic crises refractory to diazepam and clonidine. To the best of our knowledge this is the first report of intranasal dexmedetomidine for the treatment of adrenergic crisis in patients with autonomic disorders.
Case series Patient 1
Patient 1 was a 20-year-old man with genetically confirmed FD and frequent episodes of adrenergic crisis (6-8 per year), usually associated with a respiratory infection. He was typically treated with diazepam 10 mg every 12 h and clonidine 0.1 mg every 4-6 h, administered by gastrostomy tube. He had been having intermittent adrenergic crises with hypertension, tachycardia, nausea/retching, drooling and personality changes for over 1 month. Each episode lasted up to 3-4 days. During a prolonged adrenergic crisis episode [heart rate (HR) of 130 bpm], his father (a physician) administered intranasal dexmedetomidine at a dose of 2 mcg/kg, 43 mcg in each nostril. Twenty minutes later, his blood pressure (BP) and HR returned to pre-crisis values and the agitation, nausea and retching had ceased, and he fell asleep. Symptoms resumed after 137 min, and the administration of intranasal dexmedetomidine was repeated three additional times, with 146, 343 and 300 min between each of the three subsequent administrations. The average onset of symptom alleviation was 12 min ( Table 1 ). The total dose of intranasal dexmedetomidine was 344 mcg over a period of 17 h. The patient reported no local adverse effects related to the administration of intranasal dexmedetomidine. He was brought into the hospital after the fourth administration due to the cyclical reoccurrence of adrenergic crises to investigate possible underlying causes, and was found to have intestinal pseudo-obstruction with diffusely dilated large bowel. Intravenous dexmedetomidine was required for the control of adrenergic crisis while he was in the hospital. His crisis stopped after successful bowel decompression. It is unclear if decreased gastrointestinal motility was the cause of adrenergic crisis, a result of prolonged adrenergic crisis or a side effect of dexmedetomidine.
Patient 2
Patient 2 was a 43-year-old man with genetically confirmed FD and frequent episodes of anxiety-induced adrenergic crisis who developed hypertension, tachycardia, nausea/ retching, blotching and irritability 1 h after eating dinner at home. He received a total of 40 mg of diazepam (rectally) over the course of 12 h while at home without resolution of the crisis and was taken to the emergency room. At that time, his temperature was 36.5°C, BP was 174/97 mmHg and his HR was 108 bpm; he also had severe nausea and irritability. Physical examination was unremarkable. At the emergency room, he received an initial dose of intranasal dexmedetomidine (2 mcg/kg, 86 mcg dose in each nostril). After 20 min, no hemodynamic response was evident, and a second intranasal dexmedetomidine dosage was administered (86 mcg in each nostril). After 10 min, his BP fell to 140/80 mmHg, his HR slowed to 70 bpm, and he became calmer (Table 1) . He was discharged from the emergency room. He reported no local adverse effects related to the administration of intranasal dexmedetomidine. However, the next day his crisis resumed, and he was admitted to the intensive care unit (ICU) for intravenous dexmedetomidine. Because no medical cause was uncovered after extensive diagnostic work-up, it was assumed that anxiety triggered his crisis, as had occurred in the past. He was discharged 3 days later.
Patient 3
Patient 3 was a 26-year-old woman with genetically confirmed FD who developed signs and symptoms of adrenergic crisis, including hypertension (BP 169/70 mmHg), tachycardia (HR 103 bpm), nausea/retching, drooling and psychomotor agitation. Comorbidities included chronic lung disease, asthma, diarrhea/constipation, chronic kidney disease stage I, anemia of chronic disease and cholecystectomy. At home she received 7.5 mg of diazepam and 0.1 mg of clonidine by gastrostomy tube over a 4-h period, with no improvement; she was therefore instructed to come to our out-patient clinic for evaluation. Upon arrival, she was pale and uncomfortable, retching and drooling. Her BP was 169/93 mmHg, HR was 98 bpm and oxygen saturation was 98% on room air. Physical examination was significant for diffuse abdominal pain. She received intranasal dexmedetomidine at a dose of 2 mcg/kg (100 mcg given intranasal, split dose in half, one half given in each nostril). Nine minutes following the administration of the intranasal dose, the BP fell to 106/92 mmHg, the HR was stable at 100 bpm and retching abated; she then became calm and comfortable (Table 1) . There was no recurrence of symptoms in the following 2 h, and she was discharged home. She reported no local adverse effects related to the administration of intranasal dexmedetomidine. Unfortunately, crisis resumed the next day (12 h after the last intranasal dexmedetomidine dose), and she was admitted to the ICU for intravenous dexmedetomidine. Diagnostic work-up revealed mycoplasma pneumonia. The crisis resolved after a 5-day course of azithromycin.
Discussion
This case series illustrates the feasibility, safety and potential usefulness of intranasal dexmedetomidine to control refractory adrenergic crises in patients with FD. We had previously reported that the intravenous formulation of dexmedetomidine was safe and effective to treat adrenergic crises in these patients without causing respiratory depression [2] .
There is emerging literature on the safety and tolerability of intranasal dexmedetomidine [8] . In most of these studies dexmedetomidine was used for pre-procedural sedation. A study of six healthy subjects compared intranasal and intravenous administration of dexmedetomidine for sedation [3] . Following intranasal dexmedetomidine 84 mcg, peak plasma concentrations were achieved in an average of 30 min (range 15-60 min) and the absolute bioavailability was 65% (range: 35-93%). Onset of action was faster in the intravenous group, but the pharmacologic effects were similar in both the intranasal and intravenous groups. The authors of the study concluded that intranasal dexmedetomidine is rapidly and efficiently absorbed and is a good alternative to intravenous dexmedetomidine for light sedation [1, 3] .
Our case series is the first report on the use of intranasal dexmedetomidine for the acute treatment of adrenergic crises in patients with FD. We suspect that hypertensive crises in patients with other disorders of the autonomic nervous system causing increased sympathetic activity (e.g. acquired baroreflex failure) may also be responsive to intranasal dexmedetomidine. This case series also supports the potential of intranasal dexmedetomidine to acutely abort adrenergic crisis in the outpatient setting (as in patient #1). Since the introduction of benzodiazepines and clonidine over 30 years ago, there have been no novel outpatient therapies for acute adrenergic crisis in patients with FD. The availability of a safe medication that can be administered intranasally is an important advance for these patients, particularly because unlike diazepam, which is currently the main at-home treatment for adrenergic crises, dexmedetomidine does not cause respiratory depression.
In all three cases reported here, intranasal dexmedetomidine was well tolerated by the patients and was not associated with adverse events. A potential side effect that should be monitored in this population is decreased gastrointestinal motility and ileus. This is a known side effect of dexmedetomidine and occurs not infrequently with adrenergic crisis. Dexmedetomidine could further exacerbate decreased gastrointestinal motility in patients with FD. This should be closely monitored in future studies. Although the intranasal route warrants monitoring for damage to the nasal mucosa, no nasal side effects have been reported in the literature for intranasal dexmedetomidine in the pediatric pre-sedation studies.
As expected based on its short half-life, the therapeutic effect of intranasal dexmedetomidine was short lasting. All three patients eventually required admission for work-up and treatment of the underlying cause of their crisis and also required longer intravenous dexmedetomidine treatment while hospitalized. In all three patients, we used an intranasal dosage of 2 mcg/kg based on pediatric pre-procedural sedation studies. Perhaps a higher initial dose or repeated doses of intranasal dexmedetomidine would have been more effective and last longer.
Patients with FD and refractory autonomic crises require a comprehensive diagnostic work-up to identify the underlying medical cause for their episode, which may not be readily apparent. If an underlying medical illness is found as a trigger, it must be managed appropriately in order for the crisis to abate. In those situations, intranasal dexmedetomidine is solely intended for symptomatic treatment of the crisis, until the triggering factor can be addressed.
The limitations of this case series include its small sample size and the non-controlled observational design. In addition, the optimal dose of intranasal dexmedetomidine is not defined, and patients may require higher or more frequent dosages than the ones we used. Indeed, for safety purposes we used pediatric dosing, although all three patients were adults. The second patient was overweight, which is particularly uncommon in FD and may have required further upward dose adjustment.
In conclusion, this case series shows that intranasal dexmedetomidine is a feasible and apparently safe treatment for adrenergic crisis in patients with FD. Further controlled studies are required to confirm its safety and efficacy in this fragile medical population.
